MG132, a proteasome inhibitor, attenuates pressure-overload-induced cardiac hypertrophy in rats by modulation of mitogen-activated protein kinase signals

Acta Biochimica et Biophysica Sinica

Volumn 42, Issue 4, 2010, Pages 253-258

  Chen, Baolin ^a,b   Ma, Yuedong ^a,c   Meng, Rongsen ^a   Xiong, Zhaojun ^a   Zhang, Chengxi ^a   Chen, Guangqin ^a   Zhang, Aixia ^a   Dong, Yugang ^a,c  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUIZHOU PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

Abdominal aortic banding; Cardiac hypertrophy; MAPK; MG132; Signal transduction

Indexed keywords

BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; LEUPEPTIN; PROTEASOME; PROTEINASE INHIBITOR;

ANIMAL; AORTA; ARTICLE; CARDIOMEGALY; DRUG ANTAGONISM; ECHOCARDIOGRAPHY; HEART VENTRICLE; MALE; METABOLISM; METHODOLOGY; PATHOLOGY; PHOSPHORYLATION; PRESSURE; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; AORTA; CARDIOMEGALY; ECHOCARDIOGRAPHY; HEART VENTRICLES; LEUPEPTINS; MALE; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; PRESSURE; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

RATTUS;

EID: 77950553729     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmq012     Document Type: Article

References (30)

1. Frey N, Katus HA, Olson EN and Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation 2004, 109: 1580-1589.
2. Ahuja P, Sdek P and MacLellan WR. Cardiac myocyte cell cycle control in development, disease, and regeneration. Physiol Rev 2007, 87: 521-544.
3. Glickman MH and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002, 82: 373-428.
4. Meiners S, Dreger H, Fechner M, Bieler S, Rother W, Gunther C and Baumann G, et al. Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension 2008, 51: 302-308.
5. Palombella VJ, Rando OJ, Goldberg AL and Maniatis T. The ubiquitinproteasome pathway is required for processing the NF-kB1 precursor protein and the activation of NF-kB. Cell 1994, 78: 773-785.
6. Folco EJ and Koren G. Degradation of the inducible cAMP early repressor (ICER) by the ubiquitin-proteasome pathway. Biochem J 1997, 328: 37-43.
7. Powell SR, Wang P, Katzeff H, Shringarpure R, Teoh C, Khaliulin I and Das DK, et al. Oxidized and ubiquitinated proteins may predict recovery of postischemic cardiac function: essential role of the proteasome. Antioxid Redox Signal 2005, 7: 538-546.
8. Kumarapeli AR, Horak KM, Glasford JW, Li J, Chen Q, Liu J and Zheng H, et al. A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin. FASEB J 2005, 19: 2051-2053.
9. Depre C, Wang Q, Yan L, Hedhli N, Peter P, Chen L and Hong C, et al. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 2006, 114: 1821-1828.
10. Bahrudin U, Morisaki H, Morisaki T, Ninomiya H, Higaki K, Nanba E and Igawa O, et al. Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy. J Mol Biol 2008, 384: 896-907.
11. Sarikas A, Carrier L, Schenke C, Doll D, Flavigny J, Lindenberg KS and Eschenhagen T, et al. Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovasc Res 2005, 66: 33-44.
12. Doll D, Sarikas A, Krajcik R and Zolk O. Proteomic expression analysis of cardiomyocytes subjected to proteasome inhibition. Biochem Biophys Res Commun 2007, 353: 436-442.
13. Ding Q, Dimayuga E, Markesbery WR and Keller JN. Proteasome inhibition induces reversible impairments in protein synthesis. FASEB J 2006, 20: 1055-1063.
14. Meiners S, Laule M, Rother W, Guenther C, Prauka I, Muschick P and Baumann G, et al. Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation 2002, 105: 483-489.
15. Yuan BZ, Chapman JA and Reynolds SH. Proteasome inhibitor MG132 induces apoptosis and inhibits invasion of human malignant pleural mesothelioma cells. Transl Oncol 2008, 1: 129-140.
16. Liu L, Yang C, Herzog C, Seth R and Kaushal GP. Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity. Biochem Pharmacol 2010, 79: 137-146.
17. Nalepa G, Rolfe M and Harper JW. Drug discovery in the ubiquitinproteasome system. Nat Rev Drug Discov 2006, 5: 596-613.
18. Diallo JS, Betton B, Parent N, Peant B, Lessard L, Le PC and Bertrand R, et al. Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors. Br J Cancer 2008, 99: 1613-1622.
19. Meng RS, Pei ZH, Yin R, Zhang CX, Chen BL, Zhang Y and Liu D, et al. Adenosine monophosphate-activated protein kinase inhibits cardiac hypertrophy through reactivating peroxisome proliferator-activated receptor-alpha signaling pathway. Eur J Pharmacol 2009, 620: 63-70.
20. Zolk O, Schenke C and Sarikas A. The ubiquitin-proteasome system: focus on the heart. Cardiovasc Res 2006, 70: 410-421.
21. Mitch WE and Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 1996, 335: 1897-1905.
22. Dreger H, Westphal K, Weller A, Baumann G, Stangl V, Meiners S and Stangl K. Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovasc Res 2009, 83: 354-361.
23. Luss H, Schmitz W and Neumann J. A proteasome inhibitor confers cardioprotection. Cardiovasc Res 2002, 54: 140-151.
24. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 2007, 116: 1413-1423.
25. Esposito G, Prasad SV, Rapacciuolo A, Mao L, Koch WJ and Rockman HA. Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase activity in in vivo pressure overload. Circulation 2001, 103: 1453-1458.
26. Klein G, Schaefer A, Hilfiker-Kleiner D, Oppermann D, Shukla P, Quint A and Podewski E, et al. Increased collagen deposition and diastolic dysfunction but preserved myocardial hypertrophy after pressure overload in mice lacking PKCepsilon. Circ Res 2005, 96: 748-755.
27. Bueno OF, de Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R and Hewett TE, et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 2000, 19: 6341-6350.
28. Purcell NH, Darwis D, Bueno OF, Muller JM, Schule R and Molkentin JD. Extracellular signal-regulated kinase 2 interacts with and is negatively regulated by the LIM-only protein FHL2 in cardiomyocytes. Mol Cell Biol 2004, 24: 1081-1095.
29. Liang Q, Bueno OF, Wilkins BJ, Kuan CY, Xia Y and Molkentin JD. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through crosstalk with calcineurin-NFAT signaling. EMBO J 2003, 22: 5079-5089.
30. Frey N and Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003, 65: 45-79.